Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment

Boudou, L.; Gerbay, B.; Chopin, Florence; Ollagnier, E.; Collet, Philippe; Thomas, Thierry

doi:10.1007/s00198-011-1638-6

Cited by 76 publications

(39 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2011, the FLS at the University Hospital of St. Etienne, France evaluated adherence among 155 fracture patients who were initially prescribed a specific osteoporosis treatment by the FLS [131]. Among the 90% of patients (n=140) who actually used the prescription to begin treatment, 80% were still taking treatment at 12 months.…”

Section: Adherence To Treatmentmentioning

confidence: 99%

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

et al. 2017

View full text Add to dashboard Cite

-none for this submission. EVM -none for this submission. JAK and PJM have undertaken consultancy for governments, national osteoporosis societies, healthcare professional organisations and private sector companies relating to systematic approaches to fragility fracture care and prevention. JYR has no disclosures related to this work, and has received consultancy, lecture fees and grant support from Amgen, Analis, Asahi Kasei, Boehringer, Bristol Myers Squibb, Chiltern, Danone, Ebewee Pharma, Endocyte, Galapagos, GlaxoSmithKline, IBSAGenevrier, Lilly, Merck Sharp and Dohme, Merckle, Negma, Novartis, NovoNordisk, NPS, Nycomed-Takeda, Organon, Pfizer, PharmEvo, Radius Health, Roche, Rottapharm, Servier, Teijin, Teva, Theramex, Therabel, UCB, Will Pharma, Wyeth, Zodiac. NCWH has no disclosures related to this work, and has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma. PJM serves as a consultant to the International Osteoporosis Foundation and received remuneration for his contribution to this manuscript. RR has received honoraria for participation in Advisory boards or speaker bureau fees from Danone, Labatec, Nestlé, and ObsEva. Introduction-This narrative review considers the key challenges facing healthcare professionals and policymakers responsible for providing care to populations in relation to bone health. These challenges broadly fall into 4 distinct themes: Europe PMC Funders Group

show abstract

Section: Adherence To Treatmentmentioning

confidence: 99%

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The Role of Fracture Liaison Services in Re-Fracture Prevention 283 Lih et al, 2011), US (three studies - Edwards et al, 2005;Dell et al, 2008;Navarro et al, 2011), Canada (three studies - Bogoch et al, 2006;Majumdar et al, 2007Morrish et al, 2009) and Europe (two studies - Clunie et al, 2008;Boudou et al, 2011). A further two studies focused on the cost analysis of individual FLS (Sander et al, 2008;Cooper et al, 2011).…”

Section: 'Type A' Models Of Carementioning

confidence: 99%

“…All except one study [Boudou et al, 2011] evaluated male and female patients, with information on racial background being reported in 3 out of 11 studies [Majumdar et al, 2007Navarro et al, 2011]. The number of patients ranged from 46 to 620,000, but most studies included between 200 to 400 subjects.…”

Section: Non-frail Frailmentioning

confidence: 99%

“…Two cross-sectional studies have described the implementation of a 'Type A' fracture liaison service, one from the United Kingdom [Clunie et al, 2008] and one from France [Boudou et al, 2011]. Clunie and co-workers recruited 2491 male or female patients older than 50 years with a minimal trauma fracture at any site.…”

Section: Study Types and Patient Characteristicsmentioning

confidence: 99%

“…More than 50% of patients had a hip or wrist fracture. The study by Boudou et al (2011), evaluated 155 female patients over 50 years of age with wrist, humerus or femur fractures. Racial background was not reported in either study.…”

Section: Study Types and Patient Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

The Role of Fracture Liaison Services in Re-Fracture Prevention

Ganda¹,

Seibel²

2012

Primary Care at a Glance - Hot Topics and New Insights

View full text Add to dashboard Cite

Patient Outcomes in the Years After a DXA-BMD Treatment Monitoring Test: Improved Medication Adherence in Some, But Too Little Too Late

Kline

Lix

Leslie

2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

The role of mid‐treatment monitoring dual‐energy X‐ray absorptiometry–bone mineral density (DXA‐BMD) for bisphosphonate‐treated patients with osteoporosis remains unsettled. A common reason for such monitoring is to encourage ongoing medication adherence. We sought to determine if a DXA‐BMD treatment monitoring test was associated with improved medication adherence and whether improved adherence after a DXA‐BMD treatment monitoring test was associated with subsequent reduction in fracture rates. Using linked administrative databases within Manitoba, Canada, we performed a retrospective cohort study of women starting and continuing antiresorptive therapy in whom a mid‐treatment DXA‐BMD monitoring test was performed. From the provincial pharmacy database, we estimated medication adherence by calculating annual medication possession ratio (MPR) and determining the change in MPR with respect to change (stable/decrease) in the DXA‐BMD monitoring test, in addition to fracture rates before and after the test. The cohort comprised 3418 women, 90.7% treated with oral bisphosphonate, with pharmacy data for the 3 years before and after the mid‐treatment DXA‐BMD. Median (interquartile range) MPR was 0.84 (0.49–0.99) in the year before DXA‐BMD and 0.84 (0.48–0.99) in the year after DXA‐BMD (p = 0.37). Among those whose DXA‐BMD declined, MPR in the prior year was 0.54 (0.04–0.92) but improved to 0.70 (0.31–0.92) in the year after DXA‐BMD (p < 0.001). Among those whose DXA‐BMD monitoring test was stable/improved, the fracture rate before the monitoring DXA‐BMD was 10.1 per 1000 person‐years and in those whose DXA‐BMD monitoring test showed a decrease, the rate was 23.7 per 1000 person‐years (p < 0.001). Despite improved adherence in those with DXA‐BMD decline, the post DXA‐BMD fracture rate was 22.4 per 1000 person‐years versus 12.9 per 1000 person‐years in those who had stable DXA‐BMD (p < 0.001). A mid‐treatment DXA‐BMD reassessment strategy may be useful to focus attention upon adherence, but for optimal fracture outcomes, treatment adherence should be specifically addressed at the commencement of therapy. © 2021 American Society for Bone and Mineral Research (ASBMR).

show abstract

Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment

Cited by 76 publications

References 41 publications

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

The Role of Fracture Liaison Services in Re-Fracture Prevention

Patient Outcomes in the Years After a DXA-BMD Treatment Monitoring Test: Improved Medication Adherence in Some, But Too Little Too Late

Contact Info

Product

Resources

About